SEC Form 4Coverage since Jun 1, 2026
$MDGL insider trading
Over the last 12 months, Madrigal Pharmaceuticals insiders reported no purchases and 2 sales totaling $1.9M across SEC Form 4 filings. 50% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.9M 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 50% pre-arranged plans
Side
Price · $MDGL · 12Mvia TradingView
Top insiders · 12m
Soergel DavidChief Medical Officer1× · $517K
Sibold William JohnPresident and CEO1× · $1.4M
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Sibold William JohnPresident and CEO · O·D | ▼ Sale | 2,500 | $547.3 | $1.4M | -1.2% | 10 tranches |
| Jun 1, 2026 | Soergel DavidChief Medical Officer · O | ▼ Sale | 1,042 | $495.74 | $517K | -9.4% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MDGL feed.